RenovoRx (RNXT) Operating Expenses (2020 - 2026)
RenovoRx (RNXT) posted Operating Expenses of $3.9 million for Q1 2026, up 5.79% sequentially from $3.7 million in Q4 2025, and up 22.88% YoY from $3.2 million in Q1 2025.
RenovoRx (RNXT) Operating Expenses (2020 - 2026) Analysis & Trends
RenovoRx has reported Operating Expenses for 7 years, with the latest figure at $3.9 million in Q1 2026.
- Quarterly Operating Expenses rose 22.88% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 million (up 19.5% YoY) and the FY2025 annual result came in at $13.3 million, up 20.82% from the prior year.
- Operating Expenses improved to $3.9 million in Q1 2026 per RNXT's latest filing, from $3.7 million in the prior quarter.
- Over five years, Operating Expenses peaked at $3.9 million in Q1 2026 and troughed at $1.8 million in Q4 2023.
- A 5-year average of $2.9 million and a median of $3.0 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 201.85% in 2022, then slipped 24.07% in 2024.
- Over 5 years, Operating Expenses stood at $2.2 million in 2022, then slipped by 18.11% to $1.8 million in 2023, then soared by 50.53% to $2.7 million in 2024, then soared by 39.51% to $3.7 million in 2025, then gained by 5.79% to $3.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $3.9 million, $3.7 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | 4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.12 Mn |
| Mar 31, 2026 | 3.95 Mn |
| Dec 31, 2025 | 3.73 Mn |
| Sep 30, 2025 | 3.41 Mn |
| Jun 30, 2025 | 2.95 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 3.03 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 2.98 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 3.26 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 2.16 Mn |
| Jun 30, 2022 | 2.61 Mn |
| Mar 31, 2022 | 3.01 Mn |
| Dec 31, 2021 | 2.36 Mn |
| Sep 30, 2021 | 1.40 Mn |